300 related articles for article (PubMed ID: 23649327)
41. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
42. Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules.
d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
Expert Opin Drug Deliv; 2014 Feb; 11(2):283-97. PubMed ID: 24313282
[TBL] [Abstract][Full Text] [Related]
43. Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling.
Nichols JW; Sakurai Y; Harashima H; Bae YH
J Control Release; 2017 Dec; 267():31-46. PubMed ID: 28807683
[TBL] [Abstract][Full Text] [Related]
44. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
45. Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy.
Kumar P; Gulbake A; Jain SK
Crit Rev Ther Drug Carrier Syst; 2012; 29(5):355-419. PubMed ID: 22876808
[TBL] [Abstract][Full Text] [Related]
46. Role of nanocarrier systems in cancer nanotherapy.
Mozafari MR; Pardakhty A; Azarmi S; Jazayeri JA; Nokhodchi A; Omri A
J Liposome Res; 2009; 19(4):310-21. PubMed ID: 19863166
[TBL] [Abstract][Full Text] [Related]
47. Tumor microenvironment-specific nanoparticles activatable by stepwise transformation.
Ko H; Son S; Jeon J; Thambi T; Kwon S; Chae YS; Kang YM; Park JH
J Control Release; 2016 Jul; 234():68-78. PubMed ID: 27164544
[TBL] [Abstract][Full Text] [Related]
48. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
49. Dextran-based doxorubicin nanocarriers with improved tumor penetration.
Sagnella SM; Duong H; MacMillan A; Boyer C; Whan R; McCarroll JA; Davis TP; Kavallaris M
Biomacromolecules; 2014 Jan; 15(1):262-75. PubMed ID: 24313925
[TBL] [Abstract][Full Text] [Related]
50. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
Li X; Wu M; Pan L; Shi J
Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
[TBL] [Abstract][Full Text] [Related]
51. Responsive Nanocarriers as an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer.
Liu Y; Xu CF; Iqbal S; Yang XZ; Wang J
Adv Drug Deliv Rev; 2017 Jun; 115():98-114. PubMed ID: 28396204
[TBL] [Abstract][Full Text] [Related]
52. Nanocarriers for the Effective Treatment of Cervical Cancer: Research Advancements and Patent Analysis.
Pathak K; Akhtar N
Recent Pat Drug Deliv Formul; 2018; 12(2):93-109. PubMed ID: 29611489
[TBL] [Abstract][Full Text] [Related]
53. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
54. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
55. Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches.
Malliappan SP; Kandasamy P; Chidambaram S; Venkatasubbu D; Perumal SK; Sugumaran A
Anticancer Agents Med Chem; 2020; 20(11):1300-1310. PubMed ID: 31642415
[TBL] [Abstract][Full Text] [Related]
56. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
57. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
58. Editorial.
Pharmacol Res; 2017 Dec; 126():1. PubMed ID: 29153292
[No Abstract] [Full Text] [Related]
59. Nanopreparations for organelle-specific delivery in cancer.
Biswas S; Torchilin VP
Adv Drug Deliv Rev; 2014 Feb; 66():26-41. PubMed ID: 24270008
[TBL] [Abstract][Full Text] [Related]
60. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
